Harnessing designed nanoparticles: Current strategies and future perspectives in cancer immunotherapy. (December 2017)

• Record Type: Journal Article
• Authors: Jo, Sung Duk; Nam, Gi-Hoon; Kwak, Gijung; Yang, Yoosoo; Kwon, Ick Chan
• Is Part Of: Nano today. Volume 17(2017)
• Page Start: 23
• Page End: 37
• Publication Date: 2017-12
• Subjects: Cancer immunotherapy -- Nanoparticles -- Targeted delivery -- Drug delivery system -- Vaccines -- Tumor immune evasion -- Exosome; Nanotechnology -- Periodicals; Nanosciences -- Périodiques; 620.505
• DOI: 10.1016/j.nantod.2017.10.008
• Languages: English
• ISSNs: 1748-0132

Abstract

Graphical abstract: Highlights: Review recent progress in nanotechnology with the potential to enhance the efficacy of cancer immunotherapies by improving delivery to specific target tissues. Discuss the characteristics and design parameters of nanoparticle delivery systems that should be considered to maximize efficacy of immunotherapies. Overview a variety of nanoparticle platforms, including polymeric and inorganic nanoparticles, liposomes, and nature-derived nanoparticles which can be engineered according to intended uses in cancer immunotherapy. Highlight translational challenges and opportunities in the field of nanoparticle-mediated cancer immunotherapy. Abstract: Although cancer immunotherapy, represented by chimeric antigen receptor (CAR) T-cell therapy and immune checkpoint-blockade therapies, has shown durable outcomes, the percentage of patients that respond to these approaches remains modest to date. However, encouraging recent advances suggest that nanotechnology has the potential to enhance the efficacy of such immunotherapies by improving the delivery, biodistribution, and release-kinetics of immunostimulatory small molecules and biologics in targeted tissues. A variety of synthetic nanoparticles, including polymeric nanoparticles, liposomes and inorganic nanoparticles, can be engineered according to their intended uses in cancer immunotherapy. Notably, nature-derived nanoparticles have emerged as a new class of immunotherapeutics. In this review, we describe state-of-the-art strategies for cancer immunotherapy using designed nanoparticles. We also highlight key translational challenges and opportunities in this rapidly growing field.